Altay Therapeutics LinkedIn · Nov 2025
Altay announced that the FDA granted Orphan Drug Designation to DX5057, described as the first and only oral small-molecule DUX4 inhibitor in development for FSHD.
Altay develops disease-modifying therapies targeting transcription…
Company research
Public company, workplace, funding, and market signals
Overview
Altay Therapeutics is a San Francisco-based biopharmaceutical company developing oral small-molecule inhibitors of transcription factors to address serious, underserved diseases. Its lead program is DX5057, an oral DUX4 inhibitor for FSHD, alongside a STAT3 program for inflammatory diseases and oncology.
Primary product
DX5057, an oral DUX4 inhibitor for facioscapulohumeral muscular dystrophy (FSHD)
Founded
2019
Headquarters
San Francisco, California, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Biopharmaceutical drug discovery
Offices
455 Mission Bay Blvd S, San Francisco, California 94158, United States (HQ)
Open Positions
0 jobs at Altay Therapeutics
No open positions
Check back later for new openings